Deutetrabenazine
Austedo (deutetrabenazine) is a small molecule pharmaceutical. Deutetrabenazine was first approved as Austedo on 2017-04-03. It is used to treat chorea and tardive dyskinesia in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Austedo, Deutetrabenazine
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| austedo | New Drug Application | 2022-05-17 |
| austedo austedo xr | New Drug Application | 2024-07-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| tardive dyskinesia | — | D000071057 | G24.01 |
| chorea | EFO_0004152 | D002819 | G25.5 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
DEUTETRABENAZINE, AUSTEDO, TEVA BRANDED PHARM | |||
| 2024-12-24 | PED | ||
| 2024-10-03 | PED | ||
| 2024-06-24 | M-54 | ||
| 2024-04-03 | ODE-134 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Deutetrabenazine, Austedo Xr, Teva | |||
| 11311488 | 2041-06-10 | DP | U-1995, U-3055 |
| Deutetrabenazine, Austedo, Teva Branded Pharm | |||
| 11179386 | 2038-03-15 | DP | U-1995, U-3055 |
| 11813232 | 2038-03-15 | DP | |
| 10959996 | 2036-03-07 | U-3055 | |
| 11357772 | 2036-03-07 | U-1995, U-3055 | |
| 11446291 | 2036-03-07 | U-1995 | |
| 11564917 | 2036-03-07 | U-1995 | |
| 11648244 | 2036-03-07 | U-1995 | |
| 9233959 | 2033-09-18 | DP | |
| 9296739 | 2033-09-18 | DP | |
| 9550780 | 2033-09-18 | DS, DP | U-1995, U-3055 |
| 9814708 | 2033-09-18 | DP | |
| 11666566 | 2033-09-18 | DP | |
| 8524733 | 2031-04-03 | DS, DP | |
HCPCS
No data
Clinical
No data
Drug
General
| Drug common name | Deutetrabenazine |
| INN | deutetrabenazine |
| Description | Austedo (dutetrabenazine) is a small molecule pharmaceutical. Dutetrabenazine was first approved as Austedo on 2017-04-03. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | [2H]C([2H])([2H])Oc1cc2c(cc1OC([2H])([2H])[2H])C1CC(=O)C(CC(C)C)CN1CC2 |
Identifiers
| PDB | — |
| CAS-ID | 1392826-25-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3137326 |
| ChEBI ID | — |
| PubChem CID | 45255840 |
| DrugBank | — |
| UNII ID | P341G6W9NB (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Austedo – Teva
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
No data
Safety
Black-box Warning
Black-box warning for: Austedo, Austedo austedo xr
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use